Effect of SLCO1B1 c.521T>C polymorphism on the lipid response to statins in people living with HIV on a boosted protease inhibitor containing regimen.

Publication

Effect of SLCO1B1 c.521T>C polymorphism on the lipid response to statins in people living with HIV on a boosted protease inhibitor containing regimen.

Journal Paper/Review - Apr 26, 2023

Marzolini Catia, Cavassini Matthias, Braun Dominique Laurent, Hachfeld Anna, Bernasconi Enos, Calmy Alexandra, Schmid Patrick, Battegay Manuel, Elzi Luigia, Swiss HIV Cohort Study SHCS

Citation

Marzolini C, Cavassini M, Braun D, Hachfeld A, Bernasconi E, Calmy A, Schmid P, Battegay M, Elzi L, Swiss HIV Cohort Study S. Effect of SLCO1B1 c.521T>C polymorphism on the lipid response to statins in people living with HIV on a boosted protease inhibitor containing regimen. Br J Clin Pharmacol 2023

Type

Journal Paper/Review (English)

Journal

Br J Clin Pharmacol 2023

Publication Date

Apr 26, 2023

Issn Electronic

1365-2125

Brief description/objective

We previously observed that some individuals on HIV boosted protease inhibitor containing regimen do not achieve their lipid targets despite elevated statin concentrations. This study evaluated whether the common single polymorphism c.521T>C in SLCO1B1, associated with reduced statin uptake in the liver, could explain this observation.